Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy – Observational prospective single institution analysis

PURPOSE: Conventional osteosarcoma is an orphan disease. Current treatment approaches include combining a three drug chemotherapy schedule and surgery. The 3- and 5-year event-free survival (EFS) in localized disease is roughly 65 and 60%, respectively. The registration study of mifamurtide reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Múdry, Peter, Kýr, Michal, Rohleder, Ondřej, Mahdal, Michal, Staniczková Zambo, Iva, Ježová, Marta, Tomáš, Tomáš, Štěrba, Jaroslav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080518/
https://www.ncbi.nlm.nih.gov/pubmed/33948428
http://dx.doi.org/10.1016/j.jbo.2021.100362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080518/
https://www.ncbi.nlm.nih.gov/pubmed/33948428
http://dx.doi.org/10.1016/j.jbo.2021.100362

Ejemplares similares